Brief: Johnson & Johnson Announces New Data For Tremfya
Mon 13:56
BRIEF-Johnson & Johnson Announces New Data For Tremfya Oct 19 (Reuters) - Johnson & Johnson JNJ.N:
ANNOUNCES NEW DATA SHOWING TREMFYA® (GUSELKUMAB) IS THE ONLY IL-23 TO DELIVER DURABLE FISTULA REMISSION THROUGH 48 WEEKS IN CROHN'S DISEASE WITH PERIANAL FISTULA
TREMFYA SAFETY FINDINGS THROUGH WEEK 48 CONSISTENT WITH ESTABLISHED PROFILE IN CROHN'S DISEASE
TREMFYA 100 MG DOSE GROUP COMBINED FISTULA REMISSION INCREASES FROM 28% AT WEEK 24 TO 35% AT WEEK 48
Source text: ID:nPn5W6sSWa
Further company coverage: JNJ.N
((Reutersbriefs@thomsonreuters.com;))
Recent news on Johnson & Johnson
See all newsEli Lilly hits record high as healthcare stocks rally
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived (updated)
Brief: Johnson & Johnson Announces New Data For Tremfya
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin